Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16889162 | 0.86 | GRM5 (0.37) | GRM5POLBTSHRLMNAALDH1A1 | |
| SCHEMBL12608295 | 0.82 | CNR2 (0.34) | POLBTSHRALDH1A1CNR2RAB9A | |
| SCHEMBL15133037 | 0.82 | CNR2 (0.34) | GRM5TSHRLMNAALDH1A1CNR2 | |
| SCHEMBL1798699 | 0.81 | CNR2 (0.37) | GRM5POLBTSHRCNR2PRMT5 | |
| SCHEMBL16963847 | 0.81 | GRM5 (0.39) | GRM5POLBTSHRLMNAALDH1A1 | |
| SCHEMBL16885248 | 0.78 | ALDH1A1 (0.36) | GRM5POLBALDH1A1CNR2PRMT5 | |
| SCHEMBL15637406 | 0.76 | GRM5 (0.38) | GRM5ALDH1A1CNR2PRMT5L3MBTL1 | |
| SCHEMBL18478526 | 0.76 | SMN1; SMN2 (0.43) | GRM5LMNAALDH1A1CNR2PRMT5 | |
| SCHEMBL25851067 | 0.76 | KMT2A (0.47) | GRM5TSHRLMNAALDH1A1CNR2 | |
| SCHEMBL25259083 | 0.74 | GRM5 (0.40) | GRM5CNR2PRMT5SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109666950-A | method for electrochemically synthesizing tetrazole compound | 浙江工业大学 | 2019-04-23 | — | — | CN | disclosed |
| US-9199996-B2 | Pyrido[4,3-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | GRM5 71/4885POLB 4270/4885TSHR 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.